Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 27, No. 1, 2006
Issue release date: December 2005
Section title: Research Article
Free Access
Tumor Biol 2006;27:17–26

Silencing the hsp25 Gene Eliminates Migration Capability of the Highly Metastatic Murine 4T1 Breast Adenocarcinoma Cell

Bausero M.A.a, c · Bharti A.a · Page D.T.a · Perez K.D.a, b · Eng J.W.-L.a · Ordonez S.L.a · Asea E.E.a, b · Jantschitsch C.d · Kindas-Muegge I.e · Ciocca D.f · Asea A.a, b
aCenter for Molecular Stress Response, Boston University Medical Center and Boston University School of Medicine, Boston, Mass., bDivision of Investigative Pathology, Department of Pathology, Scott & White Clinic and Texas A&M University System Health Science Center College of Medicine, Temple, Tex., USA; cLaboratorio de Oncología Básica y Biología Molecular, Departamento de Bioquímica, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay; dDivision of Special and Environmental Dermatology, Department of Dermatology, University of Vienna, eInstitute of Cancer Research, Vienna, Austria; fInstitute of Experimental Medicine and Biology of Cuyo (IMBECU)-CONICET, Mendoza, Argentina
email Corresponding Author

Dr. Alexzander Asea, Division of Investigative Pathology

Scott & White Clinic and The Texas A&M University System Health Science Center College of Medicine, 2401 South 31st Street

Temple, TX 76508 (USA)

Tel. +1 254 743 0201, Fax +1 254 743 0247, E-Mail asea@medicine.tamhsc.edu

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


The 25-kDa heat shock protein (Hsp25) is associated with various malignancies and is expressed at high levels in biopsies as well as circulating in the serum of breast cancer patients. In this study, we used RNA interference technology to silence the hsp25 gene in 4T1 breast adenocarcinoma cells, known as a poorly immunogenic, highly metastatic cell line. We demonstrate that transfection of 4T1 cells with short interference RNA-Hsp25 dramatically inhibits proliferation as compared with control transfected cells. In addition, we show that 4T1 cells transfected with short interference RNA-Hsp25 abrogates tumor migration potential by a mechanism that is in part due to the repression of matrix metalloproteinase 9 expression and a concomitant upregulation of its antagonist, tissue inhibitor metalloproteinase 1. Taken together, these findings provide a model system for the study of metastatic potential of tumors and are suggestive of an earlier unrecognized role for Hsp25 in tumor migration.

© 2006 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Research Article

Received: April 06, 2005
Accepted: July 07, 2005
Published online: December 30, 2005
Issue release date: December 2005

Number of Print Pages: 10
Number of Figures: 8
Number of Tables: 1

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.